Press Releases

Dario Introduces GLP-1 Behavior Change Program to Help Achieve Weight Loss Goals and Better Overall Health Outcomes

Aug 2, 2023

New program delivers whole health behavior change program to improve member health and deliver valuable insights to Dario's partners

NEW YORK, Aug. 2, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced a new program today to deliver tailored behavior change support for individuals using GLP-1s and other anti-obesity drugs. The new program will help members realize the transformational power of these new medications while improving overall health and potentially help Dario's partners gain better insights on the impact across their populations.

DarioHealth Logo


Consumers are driving a surge in demand for GLP-1s and employers and payers are working to solve for access with a limited understanding of broader clinical and financial implications. Early research highlights one key challenge: long-term adoption needed to realize the full benefits of the medications for both patients and payers, as two out of three people stop taking the drug in the first year.

GLP-1s are U.S. Food and Drug Administration-approved for use in adults with certain related chronic conditions when used in conjunction with a reduced calorie diet and increased physical activity. Dario's solution is designed to help people successfully realize their weight loss goals alongside these medications and beyond their prescription by focusing on a whole health approach. Dario's proven combination of innovative technologies and human support is proven to impact multiple chronic conditions by focusing on changing the underlying health behaviors.

Billions of data insights from Dario's decade of direct-to-consumer experience are used to drive highly personalized journeys focused on driving healthier lifestyle behaviors, and the new GLP-1 program builds on this approach to deliver long-term behavior change. Members using a GLP-1 or other anti-obesity medication who enroll in Dario's cardiometabolic solution will receive a highly personalized experience optimizing digital coaching and professional human support to improve overall health.

Members will also have access to Dario's new Medication Cabinet, a digital tool developed through collaboration with the Company's strategic partner, Sanofi US, that allows members to track their medication adherence. The new feature will help members manage their overall care and treatment plan in one place through a richer experience. Data insights available as part of Dario's solution will help partners better understand member adherence and the impact on overall member health.

"The standard of care for obesity is evolving, and we believe Dario's proven ability to sustainably change behaviors will best help our members and partners realize the full potential of these anti-obesity medications: long-term weight loss and better overall health. Our wealth of data insights today guides member engagement alongside medical weight loss interventions, and this new program adds a new dimension to the level of insights and guidance we can provide our partners on this emerging priority," said Rick Anderson, President of Dario.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses that the new program will help members realize the transformational power of medications while improving overall health and help Dario's partners gain better insights on the impact across their populations, the benefits to be realized by members using the Dario solution, and data insights available as part of Dario's solution will help partners better understand member adherence and the impact on overall member health. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact
Mary Mooney
VP Marketing

Media Contact:
Scott Stachowiak

SOURCE DarioHealth Corp.